Roche Holding | ROG - Cash And Equivalent


Roche Holding reported CHF7.55B in Cash and Equivalent for its fiscal semester ending in June of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Alcon AG USD 1.5B 90M Sep/2025
Almirall EUR 337.77M 14.83M Dec/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Fresenius EUR 1.23B 1.16B Jun/2025
Fresenius Medical Care EUR 1.58B 326.57M Dec/2025
Galapagos EUR 87.87M 23.41M Dec/2025
Genmab DKK 1.72B 46M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.25B 1.08B Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Orion EUR 160.9M 63.3M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Philips EUR 1.91B 90M Sep/2025
Recordati EUR 471.46M 129.91M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024